New Bronchoscopic Option Used for Severe Emphysema

Share this content:
New Bronchoscopic Option Used for Severe Emphysema
New Bronchoscopic Option Used for Severe Emphysema

MONDAY, Sept. 10, 2018 (HealthDay News) -- Temple University Hospital has become the first center in the U.S. to perform bronchoscopic lung volume reduction using implantation of the Zephyr Endobronchial Valve (Zephyr EBV) to treat hyperinflation associated with severe emphysema. The hospital is also the first to offer training to U.S. physicians for care and management of patients who undergo this procedure.

The Zephyr EBV is placed using a bronchoscope and flexible delivery catheter. It functions as a one-way valve allowing the damaged lobe of the lung to deflate, reducing hyperinflation. The first procedure, lasting 45 minutes, was performed on Aug. 10.

The U.S. Food and Drug Administration granted pre-market approval to the Zephyr EBV, manufactured by Pulmonx Corp., on June 29 under its breakthrough devices designation.

"This first procedure post-FDA approval is a turning point in our capabilities to treat severe emphysema using a minimally invasive bronchoscopic option," Gerard J. Criner, M.D., chair of thoracic medicine and surgery at Temple University, said in a statement. "We are very excited to be able to clinically offer this therapy to patients with severe emphysema who remain symptomatic despite optimal medical care."

More Information

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Trending Activities

All Professions

Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

Global Prevalence of Insufficient Activity 27.5 Percent

Global Prevalence of Insufficient Activity 27.5 Percent

Levels of insufficient physical activity stable between 2001, 2016; increase seen in high-income countries

HTN Tx Intensification Common Upon Discharge in U.S. Vets

HTN Tx Intensification Common Upon Discharge in U.S. ...

Fourteen percent of older adults admitted to hospital for non-cardiac conditions had intensification of tx

Quarterly Canakinumab Reduces Risk for Gout Attacks

Quarterly Canakinumab Reduces Risk for Gout Attacks

Doesn't affect serum uric acid levels over time, but targets interleukin-1β

is free, fast, and customized just for you!




Already a member?

Sign In Now »